Jazz Pharmaceuticals (JAZZ) PT Raised to $235 at Barclays
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $245.78 +0.33%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Join SI Premium – FREE
Barclays analyst Balaji Prasad raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $235.00 (from $233.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Biotech funding rises 75% this year as M&A activity continues
- Securitize Corp (SECZ) PT Lowered to $10 at Benchmark as Stock Plummets Post Q2 Earnings
- Menicon (7780:JP) PT Raised to JPY2,400 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
